BillionToOne is a precision diagnostics company structured around making molecular diagnostics more accurate, efficient and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level with principals of the firm working on development of a molecular counting technology for noninvasive prenatal testing (NIPT). The firm offers UNITY, a noninvasive pre-natal screening that tests fetal cell-free DNA for cystic fibrosis (CF) and spinal muscular atrophy (SMA) through a single sample of the mother's blood. Every year around the world, more than 3,000,000 babies are born with serious genetic defects. BillionToOne's novel technology can detect even single-gene disorders such as thalassemia through a simple blood test elminating the need for amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test.
